Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-type Glutaminase (KGA)

Overview

Journal Sci Rep

Specialty Science

Date 2014 Jan 24

PMID 24451979

Citations 49

Authors

K Thangavelu

Qing Yun Chong

Boon Chuan Low

J Sivaraman

Affiliations

Soon will be listed here.

Abstract

Glutaminase is a metabolic enzyme responsible for glutaminolysis, a process harnessed by cancer cells to feed their accelerated growth and proliferation. Among the glutaminase isoforms, human kidney-type glutaminase (KGA) is often upregulated in cancer and is thus touted as an attractive drug target. Here we report the active site inhibition mechanism of KGA through the crystal structure of the catalytic domain of KGA (cKGA) in complex with 6-diazo-5-oxo-L-norleucine (DON), a substrate analogue of glutamine. DON covalently binds with the active site Ser286 and interacts with residues such as Tyr249, Asn335, Glu381, Asn388, Tyr414, Tyr466 and Val484. The nucleophilic attack of Ser286 sidechain on DON releases the diazo group (N2) from the inhibitor and results in the formation of an enzyme-inhibitor complex. Mutational studies confirmed the key role of these residues in the activity of KGA. This study will be important in the development of KGA active site inhibitors for therapeutic interventions.

Citing Articles

Parallel multiOMIC analysis reveals glutamine deprivation enhances directed differentiation of renal organoids.

Sarami I, Hekman K, Gupta A, Snider J, Ivancic D, Zec M bioRxiv. 2025; .

PMID: 40060393 PMC: 11888470. DOI: 10.1101/2025.02.27.640060.

Debut of enzyme-responsive anionic cyanine for overlap-free NIR-II-to-I dual-channel tumour imaging.

Chu F, Feng B, Zhou Y, Liu M, Zhang H, Liu M Chem Sci. 2025; 16(10):4490-4500.

PMID: 39926710 PMC: 11801379. DOI: 10.1039/d4sc06459c.

Anticancer Effects of the Trivalent Organoarsenical 2-Amino-4-(dihydroxyarsinoyl) Butanoate.

Sarkarai Nadar V, Yoshinaga-Sakurai K, Rosen B Organometallics. 2024; 43(10):1137-1142.

PMID: 38817537 PMC: 11134607. DOI: 10.1021/acs.organomet.4c00082.

Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.

Fan Y, Xue H, Li Z, Huo M, Gao H, Guan X Front Pharmacol. 2024; 15:1345522.

PMID: 38510646 PMC: 10952006. DOI: 10.3389/fphar.2024.1345522.

Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction.

Zodda E, Tura-Ceide O, Mills N, Tarrago-Celada J, Carini M, Thomson T Elife. 2023; 12.

PMID: 38014932 PMC: 10871716. DOI: 10.7554/eLife.86260.

References

Vagin A, Teplyakov A . Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):22-5. DOI: 10.1107/S0907444909042589. View

BARCLAY R, PHILLIPPS M . Effects of 6-diazo-5-oxol-norleucine and other tumor inhibitors on the biosynthesis of nicotinamide adenine dinucleotide in mice. Cancer Res. 1966; 26(2):282-6. View

Gill H, Eisenberg D . The crystal structure of phosphinothricin in the active site of glutamine synthetase illuminates the mechanism of enzymatic inhibition. Biochemistry. 2001; 40(7):1903-12. DOI: 10.1021/bi002438h. View

AHLUWALIA G, Grem J, Hao Z, Cooney D . Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990; 46(2):243-71. DOI: 10.1016/0163-7258(90)90094-i. View

DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20. DOI: 10.1016/j.cmet.2007.10.002. View

Sun Q, Collins R, Huang S, Holmberg-Schiavone L, Anand G, Tan C . Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S. J Biol Chem. 2008; 284(5):3076-3085. DOI: 10.1074/jbc.M805459200. View

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

Aledo J, Olalla L, Marquez J . Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome. 2000; 11(12):1107-10. DOI: 10.1007/s003350010190. View

Seltzer M, Bennett B, Joshi A, Gao P, Thomas A, Ferraris D . Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010; 70(22):8981-7. PMC: 3058858. DOI: 10.1158/0008-5472.CAN-10-1666. View

10.

Ovejera A, Houchens D, Catane R, Sheridan M, Muggia F . Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res. 1979; 39(8):3220-4. View

11.

DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F . Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry. 2011; 50(50):10764-70. DOI: 10.1021/bi201613d. View

12.

Garber K . Oncology's energetic pipeline. Nat Biotechnol. 2010; 28(9):888-91. DOI: 10.1038/nbt0910-888. View

13.

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

14.

Shapiro R, Clark V, Curthoys N . Covalent interaction of L-2-amino-4-oxo-5-chloropentanoic acid with rat renal phosphate-dependent glutaminase. Evidence for a specific glutamate binding site and of subunit heterogeneity. J Biol Chem. 1978; 253(19):7086-90. View

15.

Curthoys N, Watford M . Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995; 15:133-59. DOI: 10.1146/annurev.nu.15.070195.001025. View

16.

Wang J, Erickson J, Fuji R, Ramachandran S, Gao P, Dinavahi R . Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18(3):207-19. PMC: 3078749. DOI: 10.1016/j.ccr.2010.08.009. View

17.

Kenny J, Bao Y, Hamm B, Taylor L, Toth A, Wagers B . Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase. Protein Expr Purif. 2003; 31(1):140-8. DOI: 10.1016/s1046-5928(03)00161-x. View

18.

Shijie J, Takeuchi H, Yawata I, Harada Y, Sonobe Y, Doi Y . Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exp Med. 2009; 217(2):87-92. DOI: 10.1620/tjem.217.87. View

19.

Ortlund E, LaCount M, Lewinski K, Lebioda L . Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. Biochemistry. 2000; 39(6):1199-204. DOI: 10.1021/bi991797d. View

20.

Rajagopalan K, DeBerardinis R . Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med. 2011; 52(7):1005-8. PMC: 3337771. DOI: 10.2967/jnumed.110.084244. View